GlobeNewswire by notified

Novozymes and Chr. Hansen receive binding tax ruling that the proposed merger can be completed as a tax-exempt merger

Share

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART), IN OR INTO THE UNITED STATES, CANADA, SOUTH AFRICA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION WHERE SUCH ACTION WOULD BE UNLAWFUL.

JANUARY 24, 2023

On December 12, 2022, Novozymes A/S ("Novozymes") and Chr. Hansen Holding A/S ("Chr. Hansen") announced that Novozymes and Chr. Hansen propose to combine and create a leading global biosolutions partner by way of a statutory merger of the two companies (the "Merger"). Reference is made to Chr Hansen's company announcement no. 13 of December 12, 2022.

As described in company announcement no. 13 of December 12, 2022, the Merger is intended to be completed as a tax-exempt merger according to the Danish Merger Tax Act (in Danish "Fusionsskatteloven"). In order to confirm that the relevant requirements are met for a tax-exempt merger, Novozymes and Chr. Hansen have requested a binding ruling from the Danish tax authorities.

Today, the Danish Tax Assessment Council (in Danish: "Skatterådet") has confirmed that the relevant requirements are met for a tax-exempt merger by rendering a binding ruling confirming the joint application from Novozymes and Chr. Hansen.

The exemption document that will be published before the respective extraordinary general meetings of Novozymes and Chr. Hansen resolving on the Merger will contain additional information on taxation in relation to the proposed Merger.

Completion of the Merger is subject to, among others, approval by the extraordinary general meetings in Novozymes and Chr. Hansen, respectively, and regulatory approvals.

Transaction website
For additional information, visit https://www.chr-hansen.com/en/investors/proposed-merger

About Chr. Hansen
Chr. Hansen is a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical, and agricultural industries. At Chr. Hansen, we are well positioned to drive positive change through microbial solutions. We have worked for over 145 years to enable sustainable agriculture, better food and healthier living for more people around the world. Our microbial and fermentation technology platforms, including our broad and relevant collection of around 40,000 microbial strains, have game-changing potential. Matching customer needs and global trends, we continue to unlock the power of good bacteria to respond to global challenges such as food waste, global health and the overuse of antibiotics and pesticides. As the world’s most sustainable food ingredients company, we touch the lives of more than 1 billion people every day. Driven by our legacy of innovation and curiosity to pioneer science, our purpose – To grow a better world. Naturally. – is at the heart of everything we do.

About Novozymes
Novozymes is the world leader in biological solutions. Together with customers, partners, and the global community, we improve industrial performance while preserving the planet's resources and helping build better lives. As the world's largest provider of enzyme and microbial technologies, our bioinnovation enables higher agricultural yields, low-temperature washing, energy-efficient production, renewable fuel, and many other benefits that we rely on today and in the future. We call it Rethink Tomorrow.

Please see attachment.

Contact information

Novozymes:

Investor Relations

Tobias Cornelius Björklund

+45 3077 8682

tobb@novozymes.com

Press Relations

Lina Danstrup

+45 3077 0552

lind@novozymes.com

Chr. Hansen:

Investor Relations
Anders Mohr Christensen
+45 2515 2364
dkamc@chr-hansen.com

Press Relations
Sanne Seyer-Hansen
+45 6038 6207
dksash@chr-hansen.com

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Galapagos announces topline results from Phase 3 DIVERSITY trial of filgotinib in Crohn’s disease8.2.2023 22:01:00 CET | Press release

The two induction cohorts missed the co-primary endpoints of clinical remission and endoscopic response at Week 10In the maintenance phase, filgotinib 200mg once daily achieved the co-primary endpoints of clinical remission and endoscopic response at Week 58The safety findings were generally consistent with the known profile of filgotinib in rheumatoid arthritis (RA) and ulcerative colitis (UC)Galapagos decided not to submit a Marketing Authorization Application in Europe based on these topline dataGalapagos remains fully committed to filgotinib, a JAK1 preferential inhibitor orally administered once daily, and its approved indications, RA and UC, and is on track to start a Phase 3 trial in axial spondyloarthritis (AxSpA) later this year Mechelen, Belgium; 8February2023, 22:01CET; regulated information; Galapagos NV (Euronext & NASDAQ: GLPG) todayannouncedthe topline results from DIVERSITY,a global Phase 3 trial to evaluate the safety and efficacy of filgotinib,100mg or 200mg once dail

X8 AG Submits a Swiss Fintech Licence Application8.2.2023 21:21:16 CET | Press release

X8 AG submitted the application for a Swiss FinTech license according to Art. 1b Banking Act with the intention of operating a regulated global stablecoin system BAAR, Switzerland, Feb. 08, 2023 (GLOBE NEWSWIRE) -- The X8 AG team has successfully submitted the application to FINMA, the Swiss Financial Market Supervisory Authority, for the Swiss FinTech license according to Article 1b Banking Act. This marks an important step for X8 AG on its way to become a fully regulated global stablecoin system and significantly differentiating itself from the current non-regulated crypto space. Switzerland offers one of the most advanced regulatory frameworks for digital assets. X8 AG believes that designing its stablecoin system under Swiss law is the best starting point to achieve a global X8 cross-border framework for payments. Full compliance with the Swiss regulatory framework strengthens the high standards of protection for clients. X8 AG aims to empower users and their money with frictionles

GN Store Nord announces intention to initiate a rights issue8.2.2023 20:08:16 CET | Press release

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL This announcement does not constitute an offering memorandum or a prospectus as defined by Regulation (EU) No. 2017/1129 of 14 June 2017. The offer to acquire securities pursuant to the offering is made, and any investor should make their investment decision, solely on the basis of information that is contained in the prospectus to be made generally available in Denmark in connection with the offering. GN Store Nord announces intention to initiate a rights issue In accordance with our announcement on November 11, 2022, GN has conducted a comprehensive review of the appropriate capital structure. In light of the current macroeconomic environment and GN’s leverage, GN announces today that it intends to raise gross proceeds of DKK 7 billion in the first half

Nokia Corporation: Repurchase of own shares on 08.02.20238.2.2023 20:00:00 CET | Press release

Nokia Corporation Stock Exchange Release 8 February 2023 at 21:00 EET Nokia Corporation: Repurchase of own shares on 08.02.2023 Espoo, Finland – On 8 February 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL282,2294.39CEUX20,3804.39AQEU6,3784.39TQEX5,0134.38Total314,0004.39 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 2023

Interim report 2022/23 - 15% revenue growth and DKK 145 million operating profit (+25%) for the first half following a challenging second quarter8.2.2023 18:57:07 CET | Press release

ANNOUNCEMENT NO. 234 9 February 2023 Interim report for the first half of 2022/23 15% revenue growth and DKK 145 million operating profit (+25%) for the first half following a challenging second quarter Steen Søndergaard, CEO: “Following a very satisfactory 2021/22 with historically high revenue and operating profit growth rates, revenue for the first half of 2022/23 unfortunately disappointed, despite 15% growth. Second quarter sales of instruments, particularly in the North American market, were challenged by a generally more subdued investment sentiment in our primary business segment, cell-based therapy. Our order intake was mainly impacted by weakened demand from capital-sensitive development companies. On the other hand, we saw continued satisfactory growth in sales of consumables and services. Despite the unfavourable market conditions, our earnings continued to grow. While our market is currently affected by the prevailing macroeconomic environment, we have a strong underlying